| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2c8f6ff7bfe6d4f3eb0c6bacf1284229
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fcf9d7dac3a69acf14ea77810bb74b25 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-233
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 |
| filingDate |
2021-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d697d18bd3b1d1db82adf0375284ff8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8eca6897aa35f08ac510229c62ceb8ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d72aca8cc1415366060a5a0055a07d48 |
| publicationDate |
2021-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021190546-A1 |
| titleOfInvention |
Pharmaceutical composition comprising protein kinase inhibitor and chemotherapeutic drug and use thereof |
| abstract |
The present invention relates to the field of biotechnology, and in particular relates to a pharmaceutical composition comprising a protein kinase inhibitor and a chemotherapeutic drug and use thereof. It is found that in the treatment of platinum-refractory/drug-resistant relapsed advanced ovarian cancer, the remission rates of etoposide and paclitaxel in combination with chiauranib are respectively 40% and 50%, while the remission rate of etoposide alone is about 27%, the remission rate of paclitaxel alone is about 21%, indicating that the combination of chiauranib and etoposide or paclitaxel in the treatment of platinum-refractory/drug-resistant relapsed advanced ovarian cancer has achieved unexpected synergistic effects. |
| priorityDate |
2020-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |